SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wilt TJ,Thompson IM. Clinically localised prostate cancer. BMJ. 2006; 333: 11021106.
  • 2
    Etzioni R,Penson DF,Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94: 981990.
  • 3
    McGregor M,Hanley JA,Boivin JF,McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ. 1998; 159: 13681372.
  • 4
    Akin O,Hricak H. Imaging of prostate cancer. Radiol Clin North Am. 2007; 45: 207222.
  • 5
    Gleason DF,Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 5864.
  • 6
    Bailar JC3rd,Mellinger GT,Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep. 1966; 50: 129136.
  • 7
    Albertsen PC,Hanley JA,Gleason DF,Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975980.
  • 8
    Alexander RB,Maguire MG,Epstein JI,Walsh PC. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol. 1989; 141: 880882.
  • 9
    Stamey TA,Caldwell M,McNeal JE,Nolley R,Hemenez M,Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172: 12971301.
  • 10
    Partin AW,Mangold LA,Lamm DM,Walsh PC,Epstein JI,Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001; 58: 843848.
  • 11
    Postma R,de Vries SH,Roobol MJ,Wildhagen MF,Schroder FH,van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer. 2005; 103: 708716.
  • 12
    Gerber GS,Thisted RA,Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996; 276: 615619.
  • 13
    McNeal JE,Bostwick DG,Kindrachuk RA,Redwine EA,Freiha FS,Stamey TA. Patterns of progression in prostate cancer. Lancet. 1986; 1: 6063.
  • 14
    Connolly SS,O'Toole GC,O'Malley KJ, et al. Positive apical surgical margins after radical retropubic prostatectomy, truth or artefact? Scand J Urol Nephrol. 2004; 38: 2631.
  • 15
    Barthelemy Y,Gasman D,Bellot J,Chopin D,Abbou CC. Prognostic value of a positive single ultrasound-guided prostatic biopsy regarding tumor volume and intracapsular nature of prostatic adenocarcinoma. Prog Urol. 1996; 6: 920925.
  • 16
    D'Amico AV,Wu Y,Chen MH,Nash M,Renshaw AA,Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤7. Cancer. 2000; 89: 18101817.
  • 17
    Gardner TA,Lemer ML,Schlegel PN,Waldbaum RS,Vaughan EDJr,Steckel J. Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume. Br J Urol. 1998; 81: 839843.
  • 18
    Kakehi Y,Kamoto T,Ogawa O, et al. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men. Eur Urol. 2000; 37: 552558.
  • 19
    Weldon VE,Tavel FR,Neuwirth H,Cohen R. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol. 1995; 154: 10741077.
  • 20
    Boccon-Gibod LM,Dumonceau O,Toublanc M,Ravery V,Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol. 2005; 48: 895899.
  • 21
    Hoedemaeker RF,Van der Kwast TH,Schroder FH. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy. BJU Int. 2003; 92( suppl 2): 9296.
  • 22
    Allan RW,Sanderson H,Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003; 170: 370372.
  • 23
    Kim YJ,Lee SC,Chang IH, et al. Clinical significance of a single-core positive prostate cancers detected on extended prostate needle biopsy. Korean J Urol. 2006; 47: 475481.
  • 24
    Ochiai A,Troncoso P,Chen ME,Lloreta J,Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol. 2005; 174: 21642168.
  • 25
    Lee AK,Doytchinova T,Chen MH, et al. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? Urol Oncol. 2003; 21: 123127.
  • 26
    Taverna G,Colombo P,Seveso M, et al. Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy. Arch Ital Urol Androl. 2006; 78: 5760.
  • 27
    Harnden P,Shelley MD,Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer. 2007; 109: 1324.
  • 28
    Bruce RG,Rankin WR,Cibull ML,Rayens MK,Banks ER,Wood DPJr. Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Urology. 1996; 48: 7579.
  • 29
    Egevad L,Norberg M,Mattson S,Norlen BJ,Busch C. Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology. 1998; 52: 653658.
  • 30
    Furuya Y,Fuse H,Nagakawa O,Masai M. Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer. Int J Clin Oncol. 2002; 7: 109113.
  • 31
    Kakehi Y,Kamoto T,Shiraishi T, et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol. 2002; 41: 4753.
  • 32
    Ravery V,Schmid HP,Toublanc M, et al. Does the proportion of tumor tissue in biopsies reflect the extent of localized prostate cancer?. Prog Urol. 1996; 6: 386391.
  • 33
    Ravery V,Szabo J,Toublanc M, et al. A single positive prostate biopsy in 6 does not predict a low-volume prostate tumour. Br J Urol. 1996; 77: 724728.
  • 34
    Ravery V,Szabo J,Billebaud T, et al. A single positive prostatic biopsy out of 6 systematic biopsies is not correlated with the intracapsular nature of the tumor on an individual level. Prog Urol. 1996; 6: 7075.
  • 35
    Cupp MR,Bostwick DG,Myers RP,Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 1995; 153: 15431548.
  • 36
    Dietrick DD,McNeal JE,Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology. 1995; 45: 987992.
  • 37
    Wang X,Brannigan RE,Rademaker AW,McVary KT,Oyasu R. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol. 1997; 158: 14311435.
  • 38
    Wills ML,Sauvageot J,Partin AW,Gurganus R,Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology. 1998; 51: 759764.
  • 39
    Hoedemaeker RF,Van der Kwast TH,Schroder FH. The clinical significance of a small focus of well differentiated carcinoma on prostate biopsy. Nederlands Tijdschrift voor Urologie. 2001; 9: 39.
  • 40
    Miyake H,Ono Y,Park SJ,Hara I,Eto H. Pathological findings of radical prostatectomy specimens in Japanese men diagnosed on single core positive prostate biopsy in 8 with a Gleason score less than 4. Int J Urol. 2003; 10: 383386.
  • 41
    Guzzo TJ,Vira M,Hwang WT, et al. Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. Urology. 2005; 66: 361365.
  • 42
    Cheng L,Poulos CK,Pan CX, et al. Preoperative prediction of small volume cancer (less than 0.5 mL) in radical prostatectomy specimens. J Urol. 2005; 174: 898902.
  • 43
    Montesino SM,Jimenez AJ,Fernandez SP, et al. Minimal prostatic adenocarcinomas in the biopsy treated with radical prostatectomy. Actas Urol Esp. 2005; 29: 481484.
  • 44
    Zackrisson B,Aus G,Bergdahl S, et al. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol. 2004; 171: 15001503.
  • 45
    Huber J,Dallinger B,Wurnschimmel E. One positive core—do we operate too much? J Urol Urogynake. 2006; 13: 1820.
  • 46
    Augustin H,Hammerer PG,Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol. 2003; 43: 455460.
  • 47
    Roemeling S,Roobol MJ,Postma R, et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol. 2006; 50: 475482.
  • 48
    Tarjan M,Tot T. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies. Scand J Urol Nephrol. 2006; 40: 459464.
  • 49
    Terris MK,Haney DJ,Johnstone IM,McNeal JE,Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 1995; 45: 7580.
  • 50
    Schmid HP,McNeal JE,Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate- specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993; 71: 20312040.
  • 51
    Stamey TA,Freiha FS,McNeal JE,Redwine EA,Whittemore AS,Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993; 71: 933938.
  • 52
    Epstein JI,Chan DW,Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998; 160: 24072411.
  • 53
    Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911597.
  • 54
    Bott SR,Young MP,Kellett MJ,Parkinson MC;Contributors to the UCL Hospitals' Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int. 2002; 89: 886889.
  • 55
    Koppie TM,Bianco FJ,Kuroiwa K, et al. The clinical features of anterior prostate cancers. BJU Int. 2006; 98: 11671171.
  • 56
    Eastham JA,Kattan MW,Riedel E, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003; 170: 22922295.
  • 57
    Bianco FJJr,Eastham JA,Vickers AM, et al. Impact of the radical prostatectomy surgical technique and surgeon experience on freedom from cancer recurrence [Abstract 4569]. J Clin Oncol. 2006; 24: 18S.
  • 58
    Altman DG,Bland JM. Missing data. BMJ. 2007; 334: 424424.